Beyond The Numbers: 12 Analysts Discuss Elevance Health Stock
Portfolio Pulse from Benzinga Insights
Elevance Health (NYSE:ELV) has been analyzed by 12 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target has increased by 3.07% to $595.0. Analysts have recently raised their ratings and price targets, reflecting positive sentiment towards the stock. Key financial metrics such as revenue growth, net margin, ROE, and ROA are strong, although the company faces challenges in debt management.
May 30, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elevance Health has received a range of analyst ratings, with a notable increase in the average 12-month price target to $595.0. Recent analyst actions have been predominantly positive, with several raising their ratings and price targets. The company's financial performance is strong, but it faces challenges in debt management.
The increase in the average price target and the predominantly positive analyst ratings suggest a bullish short-term outlook for Elevance Health. The company's strong financial metrics further support this positive sentiment, although the high debt-to-equity ratio is a concern.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100